Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202605072 Clinical Evaluation of an Artificial Intelligence–Based Stroke Interpretation System (StroCare Suite) in Acute Stroke Management New Drug NA
N202605085 A Phase II, Double-blind study to evaluate the efficacy and safety of BB-101 (rhNEGF) for the treatment of atrophic acne scars after laser surgery New Medical Device NA
N202605105 A randomized, open-label (unblinding), crossover bioequivalence study to compare two voriconazole oral suspensions in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202605107 A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold) New Drug Phase Ⅲ
N202605135 A Large Language Model–Driven Daily Conversation Cognitive Interaction Platform: Feasibility and Preliminary Efficacy in Older Adults at High Risk of Dementia New Drug Phase Ⅱ
N202605145 Prospective validation of an AI+ECG screening tool for sudden cardiac death New Medical Device NA
N202605147 A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT) New Drug Phase Ⅲ
N202605152 Translational Development of Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) for Malignant Pleural Disease: A Pleural Fluid Biomarker Platform and a Phase I–II Bridging Pilot New Medical Technology NA
N202606003 A randomized, open-label (unblinding), parallel phase I study to compare the pharmacokinetic profile and safety of tirzepatide 2.5 mg/0.5 mL subcutaneous injection (single dose) with 40 mg and 20 mg tablets (multiple doses) in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202606005 Phase Ib/IIa, Open-label, Multicenter, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of HCB101 in Combination with Multiple Agents in Subjects with Advanced Solid Tumors New Drug Phase Ⅰ
1 2 22 23 24 25 26 27 28 31 32 / 32

TOP